A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Clinical trial NCT06330064 · RECRUITING
Trial details
- NCT number
- NCT06330064
- Sponsor
- Daiichi Sankyo
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-10
- Primary completion
- 2028-07-25
- Enrollment
- 680
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.